NP2GO review

NP2GO publishes NAD⁺ two ways on an open pricing page: $50 for an in-office treatment or $200 per vial delivered. Having a supervised option at all is unusual among mail-order platforms, and both figures sit beside its weight-loss, hormone and IV pricing without a membership wrapper. What the page does not give you is the dose or the concentration in that $200 vial, which is exactly what you would need to compare it with a monthly plan elsewhere. Its pricing page names one peptide, sermorelin at $250 per vial, with the same gap.

NP2GO is a nurse-practitioner-led hybrid practice at 800 W 18th St in Edmond, Oklahoma, founded by advanced practice registered nurse Kara De La Pena, whose footer lists membership of the Association of Oklahoma Nurse Practitioners and the American Association of Nurse Practitioners. Its pricing page says weight-loss care reaches 40 states, hormone therapy six (Oklahoma, Texas, Kansas, Washington, Florida and New York) and peptide therapy 'select states', alongside in-person services in Edmond and mobile IV hydration in the Oklahoma City metro. Its menu covers compounded semaglutide and tirzepatide on pay-as-you-go and month-to-month membership pricing, hormone therapy including BHRT, pellets and testosterone, NAD⁺, sermorelin, urgent care, IV hydration and aesthetics. Its footer claims verification by LegitScript and the Better Business Bureau.

Hybrid, and that is the point of it. NAD⁺ is offered as an in-office treatment at the Edmond clinic or as home-delivered vials, which means the option to be supervised for an infusion or injection exists here and does not at a mail-order platform. Every first-time patient gets a face-to-face virtual visit, and a nurse text line runs 8 a.m. to 8 p.m. Central. Its public pricing page is genuinely unusual in scope — weight-loss programs, hormone pathways, peptides, urgent care, IV hydration and aesthetics all carry itemized figures, and the weight-loss side offers a choice between pay-as-you-go with a $99 provider visit every three months and a month-to-month membership with no visit fees. It also runs prior authorizations for name-brand medication on pay-as-you-go plans while not accepting insurance, which is uncommon for a compounded telehealth practice. Two limits shape who this is for. Coverage depends on the service, and the site is not consistent about the headline number — 40 states on the homepage and pricing page, 38 or 39 on others — while peptide therapy, which is where sermorelin and presumably home-delivered NAD⁺ sit, is only 'available in select states' with no list. Aesthetics, urgent care visits and IV hydration are Oklahoma-only. And the site names no compounding pharmacy, describing its partners only as reputable.

The pricing page lists NAD⁺ as $50 for an in-office treatment and $200 per vial for home delivery, and sermorelin as $250 per vial for home delivery. Neither converts into a monthly cost, because a per-vial figure without a stated concentration, volume or dosing frequency says nothing about how long the vial lasts — a vial that lasts a month and a vial that lasts a week are the same $200 on that page. Ask for the milligrams per vial and the expected dosing schedule before comparing it with anything else. For context on the rest of the menu: compounded semaglutide on pay-as-you-go runs from $150 a month at the lowest dose to $350 at the highest, and tirzepatide from $250 to $600, plus a $99 provider visit every three months; the month-to-month membership is $199 or $299 for semaglutide and $299 or $399 for tirzepatide, depending on dose. Hormone therapy starts with a $149 individual initial program covering the first two consultations and lab rounds, then $199/month through a compounding pharmacy or $99 per three months through a local pharmacy. None of those is an NAD⁺ price.

Compounded; not FDA-approved. Prescription required only if a licensed nurse practitioner or clinician finds it appropriate. NP2GO states plainly on its pricing page that compounded semaglutide and tirzepatide are not FDA approved, and the same applies to its compounded NAD⁺ and sermorelin preparations, which are not reviewed by the FDA for purity and potency the way approved drugs are; the compounding pharmacy is not named. On evidence, NAD⁺ is a weak case. There are no controlled human outcome trials for injected or infused NAD⁺ — the single human intravenous study was a pharmacokinetic pilot showing that infused NAD⁺ clears from plasma quickly — and the energy, focus and mental-clarity benefits marketed for it are not established endpoints. The NAD⁺ forms with human data are the oral precursors nicotinamide riboside and nicotinamide mononucleotide, which reliably raise blood NAD⁺ levels; that is a raised biomarker, not a demonstrated clinical benefit. An in-office setting improves supervision, not the underlying evidence. Sermorelin, the one peptide it names, is a GHRH analog acting on a real pituitary axis with thin long-term human outcome data. Individual results vary.